

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Randy D. Blakely *et al.*

Serial No.: 09/888,233

Filed: June 22, 2001

For: ASSAY FOR TOXIN INDUCED  
NEURONAL DEGENERATION AND  
VIABILITY IN *C. ELEGANS*



Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: VBLT:007US/SLH

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
January 3, 2002	
Date	Priya D. Subramony

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10101121/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony  
Reg. No. P-50,939  
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: January 3, 2002

Form PTO-1449 (modified)

Atty. Docket No.  
VBLT:007US/SLHSerial No.  
09/888,233

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Randy D. Blakely *et al.*Filing Date:  
June 22, 2001Group:  
1645RECEIVED  
JAN 18 2002U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

TECH CENTER 1600/2900

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,146,826	11/14/00	Chalfie <i>et al.</i>	435	6	9/9/94
	A2	6,172,188 B1	1/9/01	Thastrup <i>et al.</i>	530	350	3/17/97

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Baffi <i>et al.</i> , "Differential expression of tyrosine hydroxylase in catecholaminergic neurons of neonatal wild-type and Nurr1-deficient mice," <i>Neuroscience</i> , 93(2):631-642, 1999.
	C2	Barker and Blakely, "Norepinephrine and Serotonin transporters. Molecular targets of antidepressant drugs," In <i>Psychopharmacology: The Fourth Generation of Progress</i> (Ed. By Bloom and Kupfer), Chapter 28: 321-333, 1995.
	C3	Braungart <i>et al.</i> , "MPTP-based test system for Parkinson's disease in <i>C. elegans</i> ," 2001 International Worm Meeting Abstract 128.
	C4	Chalfie <i>et al.</i> , "Green fluorescent protein as a marker for gene expression," <i>Science</i> , 263:802-805, 1994.
	C5	Choi <i>et al.</i> , "Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP <sup>+</sup> -induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK," <i>J. Neurosci. Res.</i> , 57:86-94, 1999.
	C6	Fradkov <i>et al.</i> , "A novel fluorescent protein from <i>Discosoma</i> coral and its mutants possesses a unique far-red fluorescence," <i>FEBS Lett.</i> , 479:127-130, 2000.
	C7	GenBank Accession Number AF115382.
	C8	Heim <i>et al.</i> , "Wavelength mutations and posttranslational autooxidation of green fluorescent protein," <i>Proc. Natl. Acad. Sci., USA</i> , 91:12501-12504, 1994.

25102469.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

VBLT:007US/SLH

09/888,233

List of Patents and Publications for Applicant's

Applicant

Randy D. Blakely *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 22, 2001

Group:

1645

Other Art

See Page 1

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1



RECEIVED

JAN 18 2002

TECH CENTER 1600/2900

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Jayanthi <i>et al.</i> , "The <i>Caenorhabditis elegans</i> gene T23G5.5 encodes and antidepressant- and cocaine-sensitive dopamine transporter," <i>Mol. Pharmacology</i> , 54:601-609, 1998.
	C10	Kitayama <i>et al.</i> , "Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA," <i>Ann. Neurol.</i> , 32(1):109-111, 1992.
	C11	Koelle <i>et al.</i> , "C. elegans gene knockout protocol," Article found at <a href="http://info.med.yale.edu/mbb/koelle/protocols_Gene_knockouts.html">http://info.med.yale.edu/mbb/koelle/protocols_Gene_knockouts.html</a> . Updated September 18, 2000.
	C12	Link <i>et al.</i> , "A transgenic C. elegans model for Parkinson's disease," 2001 International Worm Meeting Abstract 879.
	C13	Lotharius <i>et al.</i> , "Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons," <i>J. Neuroscience</i> , 19(4):1284-1293, 1999.
	C14	Miller <i>et al.</i> , "Two-color GFP expression for <i>C. elegans</i> ," <i>Biotechniques</i> , 26:914-921, 1999.
	C15	Miller <i>et al.</i> , "Dopamine transporters and neuronal injury," <i>Trends Pharm. Sci.</i> , 20:424-429, 1999.
	C16	Nass <i>et al.</i> , "6-OHDA sensitivity of dopaminergic neurons in <i>C. elegans</i> : role of the dopamine transporter and cell death pathways," Abstract. <i>Society Neuroscience</i> , 2000. Abstract found on the Society for Neuroscience website: <a href="http://www.sfn.org">http://www.sfn.org</a> , printed on December 26, 2001.

25102469.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.